Quick Answer
Gain Therapeutics, Inc. reported Total Revenue of $55.2 thousand for fiscal year 2023.
Gain Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $55.2K -60.6% |
$140.1K -15.1% |
$165.0K +471.3% |
$28.9K |
| Revenue (ASC 606) | — | — | $55.2K -58.4% |
$132.6K -1.0% |
$133.9K | — |
| Net Income | -$20.16M +1.2% |
-$20.41M +8.3% |
-$22.27M -26.6% |
-$17.59M -26.6% |
-$13.89M -288.3% |
-$3.58M |
| Diluted EPS | -$0.61 +31.5% |
-$0.89 +48.0% |
-$1.71 -15.5% |
-$1.48 -8.0% |
-$1.37 -3.0% |
-$1.33 |
| Total Assets | $22.82M +88.2% |
$12.12M -34.9% |
$18.61M -22.8% |
$24.10M -38.2% |
$38.99M +305.9% |
$9.60M |
| Cash and Equivalents | $20.84M +100.6% |
$10.39M -11.9% |
$11.79M +61.3% |
$7.31M -80.2% |
$36.88M +392.2% |
$7.49M |
| Long-Term Debt | $300.1K -8.6% |
$328.3K -26.9% |
$449.1K -9.3% |
$495.3K -16.1% |
$590.5K -17.5% |
$715.7K |
| Stockholders Equity | $18.56M +152.9% |
$7.34M -41.6% |
$12.58M -33.4% |
$18.88M -45.8% |
$34.82M +461.4% |
$6.20M +1478.7% |
| R&D Expense | $10.21M -5.4% |
$10.79M -6.3% |
$11.52M +37.5% |
$8.38M +16.9% |
$7.16M +217.1% |
$2.26M |
| Operating Income | -$18.71M +8.1% |
-$20.35M +8.5% |
-$22.25M -25.2% |
-$17.78M -28.6% |
-$13.83M -297.4% |
-$3.48M |
| Shares Outstanding | 42.07M +55.1% |
27.13M +67.4% |
16.21M +36.4% |
11.88M +195.4% |
4.02M +13.5% |
3.54M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2023 | $55.2K | +22.6% | -42.0% |
| Revenue (ASC 606) | March 31, 2023 | $55.2K | +47.0% | -42.0% |
| Net Income | September 30, 2025 | -$5.28M | -17.8% | +9.0% |
| Diluted EPS | September 30, 2025 | -$0.15 | +11.8% | +21.1% |
| Total Assets | September 30, 2025 | $10.97M | -23.6% | +11.6% |
| Cash and Equivalents | September 30, 2025 | $8.81M | -26.9% | +31.6% |
| Long-Term Debt | September 30, 2025 | $298.8K | -20.6% | -8.2% |
| Stockholders Equity | September 30, 2025 | $5.91M | -33.7% | +59.9% |
| R&D Expense | September 30, 2025 | $2.85M | +8.7% | +3.3% |
| Operating Income | September 30, 2025 | -$4.79M | -7.3% | +6.0% |
| Shares Outstanding | September 30, 2025 | 35.98M | +38.6% | +16.9% |
- Gain Therapeutics, Inc. reported Total Revenue of $55.2 thousand for fiscal year 2023.
- Gain Therapeutics, Inc. showed a decrease of -60.6% in Total Revenue compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Revenue (ASC 606) of $55.2 thousand for fiscal year 2023.
- Gain Therapeutics, Inc. showed a decrease of -58.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Net Income of -$20.16 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +1.2% in Net Income compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Diluted EPS of $0.61 per share (loss) for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +31.5% in Diluted EPS compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Total Assets of $22.82 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +88.2% in Total Assets compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Cash and Equivalents of $20.84 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +100.6% in Cash and Equivalents compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Long-Term Debt of $300.1 thousand for fiscal year 2025.
- Gain Therapeutics, Inc. showed a decrease of -8.6% in Long-Term Debt compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Stockholders Equity of $18.56 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +152.9% in Stockholders Equity compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported R&D Expense of $10.21 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed a decrease of -5.4% in R&D Expense compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Operating Income of -$18.71 million for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +8.1% in Operating Income compared to the prior fiscal year.
- Gain Therapeutics, Inc. reported Shares Outstanding of 42.07 million shares for fiscal year 2025.
- Gain Therapeutics, Inc. showed an increase of +55.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: